Compare ASPS & ANEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASPS | ANEB |
|---|---|---|
| Founded | 1999 | 2020 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.1M | 96.8M |
| IPO Year | N/A | 2021 |
| Metric | ASPS | ANEB |
|---|---|---|
| Price | $6.37 | $2.20 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 19.4K | 16.6K |
| Earning Date | 10-23-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.00 | N/A |
| Revenue | ★ $169,648,000.00 | N/A |
| Revenue This Year | $38.29 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $992.43 | ★ N/A |
| Revenue Growth | ★ 10.68 | N/A |
| 52 Week Low | $3.46 | $0.80 |
| 52 Week High | $15.96 | $3.42 |
| Indicator | ASPS | ANEB |
|---|---|---|
| Relative Strength Index (RSI) | 24.35 | 41.61 |
| Support Level | $6.14 | $2.26 |
| Resistance Level | $8.80 | $2.30 |
| Average True Range (ATR) | 0.60 | 0.10 |
| MACD | -0.22 | -0.00 |
| Stochastic Oscillator | 2.91 | 20.59 |
Altisource Portfolio Solutions SA is an integrated service provider and marketplace for the real estate and mortgage industries. It operates via two reportable segments, namely Servicer and Real Estate, which derive maximum revenue, and Origination. The Servicer and Real Estate segment provides loan servicers and real estate investors with solutions and technologies that span the mortgage and real estate lifecycle. The Origination segment provides originators with solutions and technologies that span the mortgage origination lifecycle. Altisource mainly serves financial institutions, government-sponsored enterprises, and originators in the United States, with the majority of its revenue flowing from field services and mortgage and real estate solutions.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States.